ArticleInternational journal of environmental research and public health2022
Assessing the Nationwide COVID-19 Risk in Mexico through the Lens of Comorbidity by an XGBoost-Based Logistic Regression Model.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mathematical Modeling of COVID-19 Cases and Deaths and the Impact of Vaccinations during Three Years of the Pandemic in Peru.Vaccines · 2023Article
- Evaluating the indigenous response to COVID-19 in rural Oaxaca, Mexico.Journal of global health · 2023Article
- COVID-19 infection and mortality among non-pregnant indigenous adults in Mexico 2020-2022: Impact of marginalisation.Journal of global health · 2023Article
- Hospitalized COVID-19 patients with diabetes have an increased risk for pneumonia, intensive care unit requirement, intubation, and death: A cross-sectional cohort study in Mexico in 2020.Health science reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of the new COVID-19 disease is a serious health problem that has affected a large part of the world population, especially older adults and people who suffer from a previous comorbidity. In this work, we proposed a classifier model that allows for deciding whether or not a patient might suffer from the COVID-19 disease, considering spatio-temporal variables, physical characteristics of the patients and the presence of previous diseases. We used XGBoost to maximize the likelihood function of the multivariate logistic regression model. The estimated and observed values of percentage occurrence of cases were very similar, and indicated that the proposed model was suitable to predict new cases (AUC = 0.75). The main results revealed that patients without comorbidities are less likely to be COVID-19 positive, unlike people with diabetes, obesity and pneumonia. The distribution function by age group showed that, during the first and second wave of COVID-19, young people aged ≤20 were the least affected by the pandemic, while the most affected were people between 20 and 40 years, followed by adults older than 40 years. In the case of the third and fourth wave, there was an increased risk for young individuals (under 20 years), while older adults over 40 years decreased their chances of infection. Estimates of positive COVID cases with both the XGBoost-LR model and the multivariate logistic regression model were used to create maps to visualize the spatial distribution of positive cases across the country. Spatial analysis was carried out to determine, through the data, the main geographical areas where a greater number of positive cases occurred. The results showed that the areas most affected by COVID-19 were in the central and northern regions of Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.